Analysts have clear opinions on KRYS.
Based on 6 analysts offering 12 month price targets for Krystal Biotech in the last 3 months. The average price target is $72.50 with a high forecast of $90.00 and a low forecast of $59.00. The average price target represents a 17.81% increase from the l
Krystal Biotech, Inc. (KRYS) is followed by 6 analysts on the street.
Raju Prasad from William Blair rates it a Buy with a target of —.
Similarly, Last month Gbola Amusa of Chardan Capital Reiterated a Buy with a target of $90.00.
The consensus on the street is Strong Buy.
What does Krystal Biotech, Inc.(KRYS) do ?
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery plat
Krystal Biotech, Inc. (KRYS) Insider Trades
Multiple company employees have indulged in significant insider trading. Krystal Biotech, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
Pres, CEO, 10%, Krishnan Krish S : S – Sale(-$2,562,888) of KRYS in the trading session of 2019-11-15.
Dir Janney Daniel : S – Sale(-$4,120,343) of KRYS in the trading session of 2019-08-29.
COO, 10% Krishnan Suma : P – Purchase(+$500,000) of Krystal Biotech, Inc. in the trading session of 2018-10-18.